Douglas Lane & Associates LLC Buys 12,854 Shares of Johnson & Johnson $JNJ

Douglas Lane & Associates LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 680,227 shares of the company’s stock after buying an additional 12,854 shares during the period. Johnson & Johnson accounts for 1.9% of Douglas Lane & Associates LLC’s investment portfolio, making the stock its 7th largest holding. Douglas Lane & Associates LLC’s holdings in Johnson & Johnson were worth $140,773,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. AustralianSuper Pty Ltd boosted its position in shares of Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after purchasing an additional 77,000 shares during the period. J.W. Cole Advisors Inc. increased its position in Johnson & Johnson by 2.2% during the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock worth $24,278,000 after buying an additional 2,769 shares during the period. Guinness Asset Management LTD increased its position in Johnson & Johnson by 0.4% during the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock worth $251,216,000 after buying an additional 5,994 shares during the period. Greenberg Financial Group purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $954,000. Finally, National Pension Service lifted its stake in Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after buying an additional 151,707 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $238.00 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a fifty day moving average price of $241.44 and a 200 day moving average price of $215.95. Johnson & Johnson has a 1-year low of $146.12 and a 1-year high of $251.71. The company has a market cap of $573.25 billion, a PE ratio of 21.54, a P/E/G ratio of 2.38 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst price-target increase — J&J had a price-target raise to $267, a near-term bullish signal that can support the stock if earnings and guidance align. Article Title
• Positive Sentiment: Strong Innovative Medicines growth noted by investors/letters — Institutional commentary highlights J&J’s Innovative Medicines momentum as a core growth driver underpinning YTD gains and medium-term earnings resilience. Article Title
• Positive Sentiment: TECNIS PureSee IOL clinical/real-world data spotlight — New data presented at ASCRS highlight adoption potential for J&J’s recently FDA-approved intraocular lens, supporting the company’s ophthalmology growth narrative. Article Title
• Positive Sentiment: Steady index momentum — J&J is being noted for steady momentum within the Russell 1000, which can attract passive/index flows and support valuation. Article Title
• Neutral Sentiment: Q1 preview and analyst expectations — Multiple previews (Seeking Alpha, TipRanks) emphasize tomorrow’s Q1 print and guidance as the main near-term catalyst; analysts expect continued earnings but will watch revenue mix and guidance closely. Article Title Article Title
• Neutral Sentiment: Market backdrop — A broader tech-led rally (Nasdaq) and weekly earnings calendar may lift sentiment for large-cap cyclicals, but J&J’s move will hinge more on its own results than tape action. Article Title Article Title
• Negative Sentiment: Short-term pullback and volatility risk — Recent headlines note a 1.2% pullback and intraday weakness; with Q1 due imminently, any guidance miss or cautious commentary could push shares lower. Article Title
• Negative Sentiment: Comparative pressures from higher-growth peers — Coverage comparing J&J to faster-growth names (e.g., Lilly) frames a valuation-growth tradeoff that could limit upside if investors favor high-growth pharma exposure. Article Title

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Thursday, March 5th. The Goldman Sachs Group reiterated a “buy” rating and set a $250.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 22nd. TD Cowen began coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a “buy” rating and a $250.00 price objective on the stock. HSBC lifted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Finally, Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $238.17.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.